American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

By R. Perrillo, R. Gish, Y. Falck-Ytter. Gastroenterology, 2015

682 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. (2017, background): “The risk of HBV reactivation can be classified as high ([10%), moderate (1–10%) or low (\1%).(52,202) Therefore, all candidates for chemotherapy and immunosuppressive therapy should be screened for HBsAg, anti-HBs and anti-HBc prior to immunosuppression treatment.”
Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases (2019, background): “Patients on immunosuppressive agents are at risk for reactivation of HBV infection, and guidelines have been developed recommending routine pretreatment screening of patients for hepatitis B surface antigen (HBsAg) and antibodies to hepatitis B core antigen (anti-HBc).(296-299) Based on the serologi”
Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018, background): “When monitoring at-risk patients without prophylaxis, the preferred antivirals for on-demand treatment remain first-line preferred NAs, although the evidence base is far weaker.((192)) The most commonly studied and recommended duration of prophylactic antiviral therapy is 6-12 months((205)) after di”